Real-World Experience of Risankizumab in Refractory Pediatric Inflammatory Bowel Disease. (PubMed, ACG Case Rep J) - Oct 1, 2026 - "No adverse events were reported. Risankizumab may be a promising option in refractory pediatric IBD."
Journal • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Pediatrics • IL23A • TNFA
|
|
Ali Alsarhan; Balaji Krishnamurthy; Christos Tzivinikos; Eman Elyyan; Mohammad Alhajjar
|